ライフサイエンスコーパス: cryptogenic cirrhosis

1 patitis (NASH), hereditary dyslipidaemia, or cryptogenic cirrhosis.

2 those with NASH, and NASH may be a cause of cryptogenic cirrhosis.

3 s now recognized as the most common cause of cryptogenic cirrhosis.

4 rranted in obese patients with alcoholic and cryptogenic cirrhosis.

5 s is confined to alcoholic liver disease and cryptogenic cirrhosis.

6 -M4 developed 19 months after transplant for cryptogenic cirrhosis.

7 e generally stable after transplantation for cryptogenic cirrhosis.

8 ver disease in the majority of patients with cryptogenic cirrhosis.

9 rrhosis, primary sclerosing cholangitis, and cryptogenic cirrhosis.

10 ng associated with the development of HCC in cryptogenic cirrhosis.

11 derwent orthotopic liver transplantation for cryptogenic cirrhosis.

12 ents infected with HGV who underwent OLT for cryptogenic cirrhosis.

13 tation (mean age, 50 years; M:F, 18:28) with cryptogenic cirrhosis.

14 One patient was diagnosed as cryptogenic cirrhosis.

15 included: hepatitis C (24), hepatitis B (9), cryptogenic cirrhosis (1), hemochromatosis (1), and prim

16 blood donors, 15% (5 of 33) of patients with cryptogenic cirrhosis, 27% (3 of 11) of patients with id

17 y of liver disease was hepatitis C (51%) and cryptogenic cirrhosis (29%).

18 itis, 6 with alcoholic liver disease, 4 with cryptogenic cirrhosis, 4 with biliary atresia, and 10 no

19 ur groups of recipients: 31 transplanted for cryptogenic cirrhosis, 70 for cholestatic etiologies, 40

20 ic cirrhosis, 52.6%; viral cirrhosis, 21.8%; cryptogenic cirrhosis, 8.4%; autoimmune cirrhosis, 5.8%;

21 ients with a pretransplantation diagnosis of cryptogenic cirrhosis, although the disease was generall

22 on in patients with liver disease, including cryptogenic cirrhosis and fulminant hepatic failure.

23 frequencies after liver transplantation for cryptogenic cirrhosis and hepatitis C (HCV).

24 with liver disease, including patients with cryptogenic cirrhosis and idiopathic fulminant hepatic f

25 gher incidence of liver disease secondary to cryptogenic cirrhosis and Laennec's cirrhosis.

26 idence to HGV infection not being a cause of cryptogenic cirrhosis and not being associated with the

27 ion in the keratin 18 gene in a patient with cryptogenic cirrhosis, but the importance of mutations i

28 (K8K18) mutations are found in patients with cryptogenic cirrhosis, but the role of keratin mutations

29 rify the role of HGV as a causative agent in cryptogenic cirrhosis by analyzing archival liver tissue

30 titis (NASH) is an under-recognized cause of cryptogenic cirrhosis (CC) on the basis of higher preval

31 er disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohe

32 =8940), HCV+alcohol (n=6066), NASH (n=1368), cryptogenic cirrhosis (CC; n=5856), hepatitis B virus (H

33 r of PI MZ carriers existed in patients with cryptogenic cirrhosis compared with other liver disease

34 Half of the patients with cryptogenic cirrhosis had histologic or clinical feature

35 Cryptogenic cirrhosis, hypertension, and coronary artery

36 Blood donors, patients with cryptogenic cirrhosis, idiopathic fulminant hepatic fail

37 ns in K18 may be predispose to, or result in cryptogenic cirrhosis in humans.

38 Cryptogenic cirrhosis is a common cause of liver-related

39 HGV infection in patients undergoing OLT for cryptogenic cirrhosis is about 25%.

40 n recipients who undergo transplantation for cryptogenic cirrhosis is similar to that of recipients w

41 isease for which no cause can be identified, cryptogenic cirrhosis, is a common indication for liver

42 ations previously described in patients with cryptogenic cirrhosis: K8 Tyr-53 --> His, K8 Gly-61 -->

43 he primary diagnosis was hepatitis C (n=16), cryptogenic cirrhosis (n=2), and autoimmune hepatitis (n

44 s (HCV) (n=2), HCV (n=1), alcohol (n=1), and cryptogenic cirrhosis (n=3).

45 AFLD was also defined by clinical diagnosis (cryptogenic cirrhosis, obese-diabetics with cryptogenic

46 al Parenteral Nutrition (TPN)-related (one), cryptogenic cirrhosis (one), and hepatoblastoma (one).

47 t HGV-RNA within the livers of patients with cryptogenic cirrhosis or in the HCC arising within them.

48 tio [OR], 3.2; 95% CI, 1.5-6.6; P =.002) and cryptogenic cirrhosis (OR, 11.1; 95% CI, 1.5-87.4; P =.0

49 n hepatitis C virus (HCV) liver (P <.05) and cryptogenic cirrhosis (P <.01) compared with normal cont

50 proportion of women, a greater prevalence of cryptogenic cirrhosis (P <.05) and diabetes (P <.05), an

51 he diagnoses of primary biliary cirrhosis or cryptogenic cirrhosis than younger recipients, who were

52 ->leu (H127L) K18 mutation in a patient with cryptogenic cirrhosis that is germline transmitted.

53 ipients (2003-2012) transplanted for NASH or cryptogenic cirrhosis (the NASH cohort) without pre-tran

54 s, and Mallory hyaline, and two patients had cryptogenic cirrhosis thought to represent "burned out"

55 HGV infection in recipients transplanted for cryptogenic cirrhosis was 26%.

56 Patients with cryptogenic cirrhosis were less likely to have undergone

57 unts for a large proportion of idiopathic or cryptogenic cirrhosis, which is associated with the typi

58 on were studied: 50 were diagnosed as having cryptogenic cirrhosis while 39 had nonviral chronic live

59 or alcoholic cirrhosis (group I), NASH, and cryptogenic cirrhosis with body mass index greater than